Education and Training
- M.D., Duke University School of Medicine, 1973
Solsky, Ian, William Berry, Lizabeth Edmondson, Janaka Lagoo, Joshua Baugh, Alex Blair, Sara Singer, and Alex B. Haynes. “World Health Organization Surgical Safety Checklist Modification: Do Changes Emphasize Communication and Teamwork?.” J Surg Res 246 (February 2020): 614–22. https://doi.org/10.1016/j.jss.2018.09.035.
Lagoo, Janaka, Robbie Singal, William Berry, Atul Gawande, Christine Lim, Sompob Paibulsirijit, and Joaquim Havens. “Development and Feasibility Testing of a Device Briefing Tool and Training to Improve Patient Safety During Introduction of New Devices in Operating Rooms: Best Practices and Lessons Learned..” J Surg Res 244 (December 2019): 579–86. https://doi.org/10.1016/j.jss.2019.05.056.
Tucker, Matthew D., Jason Zhu, Daniele Marin, Rajan T. Gupta, Santosh Gupta, William R. Berry, Sundhar Ramalingam, et al. “Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer..” Cancer Med 8, no. 10 (August 2019): 4644–55. https://doi.org/10.1002/cam4.2375.
Lagoo, Janaka, William R. Berry, Kate Miller, Brandon J. Neal, Luke Sato, Keith D. Lillemoe, Gerard M. Doherty, et al. “Multisource Evaluation of Surgeon Behavior Is Associated With Malpractice Claims..” Ann Surg 270, no. 1 (July 2019): 84–90. https://doi.org/10.1097/SLA.0000000000002742.
Massard, Christophe, Margitta Retz, Peter Hammerer, Fernando Quevedo, Peter C. C. Fong, William R. Berry, Howard Gurney, et al. “Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study..” In Journal of Clinical Oncology, 37:5029–5029. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5029.
Fong, Peter C. C., Margitta Retz, Alexandra Drakaki, Christophe Massard, William R. Berry, Emanuela Romano, Johann S. De Bono, et al. “Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study..” In Journal of Clinical Oncology, 37:5010–5010. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5010.
Berry, William R., Christopher Michael Pieczonka, Nicholas J. Vogelzang, Lawrence Ivan Karsh, James L. Bailen, Krista Van Velzen, Harini Kandadi, Nadeem Anwar Sheikh, and Shaker R. Dakhil. “Antigen (Ag) spread after sipuleucel-T and correlation with overall survival (OS): A real-world experience..” In Journal of Clinical Oncology, 37:e16504–e16504. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e16504.
Armstrong, Andrew J., Susan Halabi, Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Z. Szmulewitz, Daniel C. Danila, et al. “Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study..” J Clin Oncol 37, no. 13 (May 1, 2019): 1120–29. https://doi.org/10.1200/JCO.18.01731.
Petrylak, Daniel P., Philip Kantoff, Nicholas J. Vogelzang, Anthony Mega, Mark T. Fleming, Joe J. Stephenson, Richard Frank, et al. “Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer..” Prostate 79, no. 6 (May 2019): 604–13. https://doi.org/10.1002/pros.23765.
Tucker, Matthew D., Jason Zhu, William R. Berry, Sundhar Ramalingam, Tian Zhang, Michael Roger Harrison, Yuan Wu, Patrick Healy, Daniel J. George, and Andrew J. Armstrong. “Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC)..” In Journal of Clinical Oncology, 37:172–172. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.172.